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Purpose: Tomotherapy for intensity-modulated radiation has been demonstrated to reduce unnecessary
irradiations to adjacent organs at risk (OARs). The purpose of this study was to compare the dosimetric parameters
between Tomotherapy and three-dimensional conformal radiotherapy (3D-CRT) in rectal cancer patients.
Materials and methods: We redesigned three-dimensional conformal plans for 20 rectal cancer patients who had
received short-course preoperative radiotherapy with Tomotherapy. The target coverage for 3D-CRT and
Tomotherapy was evaluated with the following including the mean dose, VnGy, Dmin, Dmax, radiation conformality
index (RCI), and radical dose homogeneity index (rDHI).
Results: The mean PTV dose for Tomotherapy is significantly higher than that observed for the 3D-CRT (p = 0.043).
However, there is no significant difference in the V23.25Gy, V26.25Gy, V27.5Gy, and RCI values between Tomotherapy and
3D-CRT. However, the average rDHI (p < 0.001) value for Tomotherapy was significantly lower than that reported for
the 3D-CRT. Tomotherapy significantly lowered the mean level of irradiation doses to the bladder, small bowel, and
femur heads as compared to 3D-CRT.
Conclusions: Tomotherapy could produce a favorable target coverage and significant dose reduction for the OARs
at the expense of acceptable dose inhomogeneity of the PTV compared with 3D-CRT in rectal cancer patients.
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According to the Korean National Cancer Screening
Survey, the incidence of colorectal cancer has been
increasing gradually in Korea. In addition, colorectal
cancer is the third most common diagnosed malignancy,
with an estimated 22,000 new cases per year [1].
Conventional treatment with fractionated radiation of
50.4 Gy per 28 fractions for six weeks is a standard
regimen that has been widely accepted for positive
therapeutic outcomes of locally advanced rectal cancer,
which is based on results from prospective randomized
trials [2,3]. Compared with postoperative radiotherapy,* Correspondence: koppul@catholic.ac.kr
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reproduction in any medium, provided the orpreoperative radiotherapy demonstrated an improve-
ment in locoregional tumor control and resectability [2].
In European countries, a short-course radiation treat-
ment regimen of 25 Gy per five fractions for a week has
frequently been used due to the decreased expense and
increased convenience of a five-day irradiation for rectal
cancer patients as compared to a five-week schedule of
conventionally fractionated irradiation [4,5]. A prospect-
ive randomized study has proven that there were no sig-
nificant differences in survival and local tumor control
between conventionally fractionated and short-course ir-
radiation for locally advanced rectal cancer patients [6].
However, there have been several reports that short-
course irradiation has negative side effects including the
increased risk of late small bowel obstruction, necessitat-
ing hospital admission, and sexual dysfunction [7,8].
Therefore, clinicians have made considerable efforts toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
(A)            (B)
Figure 1 A exhibits an intensity-modulated radiotherapy image with Tomotherapy, and B shows a three-field technique with three-
diemnsional conformal radiation therapy. Tomotherapy could avoid high-dose irradiation of 22.5 Gy to the bladder which is outlined in azure.
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risk (OARs) including the small bowel and bladder to
avoid the long-term toxicity observed in rectal cancer
patients.
Recently, techniques to improve the accuracy of radi-
ation delivery to the target have advanced dramatically.
Helical Tomotherapy (Accuary Inc., Sunnyvale, CA)
which can involve image-guided radiation therapy using
a megavoltage CT scan just prior to radiation treatment
is one specific example of these advancements.
Tomotherapy can also yield intensity-modulated radi-
ation therapy (IMRT), which allows for highly conformal
distributions of the dose of radiation to the target and
minimizes the irradiation to the adjacent dose-limiting
organs. Use of the IMRT technique to decrease an un-
necessary irradiation to the bowel has been widely
reported for the treatment of gynecologic cancers [9].
However, dosimetric studies comparing IMRT andTable 1 Comparison of dose parameters for the planning
target volume between Tomotherapy and 3-dimensional
conformal radiation therapy
Parameters Tomotherapy 3D-CRT p value
Mean dose (Gy) 25.58 ± 0.35 25.19 ± 0.74 0.043
V23.25Gy (%) 99.45 ± 0.57 99.37 ± 0.86 0.225
V26.25Gy (%) 10.03 ± 25.66 10.28 ± 7.52 0.485
V27.5Gy (%) 0.26 ± 0.87 0.10 ± 0.12 0.414
Dmin (Gy) 17.97 ± 1.93 22.05 ± 2.76 < 0.001
Dmax (Gy) 27.28 ± 0.73 27.18 ± 0.38 0.588
RCI 1.01 ± 0.00 1.00 ± 0.00 0.120
rDHI 0.70 ± 0.01 0.83 ± 0.04 < 0.001
RCI radiation conformality index.
rDHI radical dose homogeneity index.
Dmin minimum dose irradiated to the planning target volume.
Dmax maximum dose irradiated to the planning target volume.
VnGy percentage of the volume receiving radiation ≥ n Gy.
3D-CRT 3-dimensional conformal radiation therapy.three-dimensional conformal radiation therapy (3D-
CRT) in rectal cancer patients are scarce and assessed
only in a small series [10]. Thus, we compared the dosi-
metric parameters between Tomotherapy and 3D-CRT




Twenty consecutive patients with rectal cancer who had
received short-course preoperative radiotherapy at Seoul
St. Mary’s Hospital, Seoul, Korea from July 2010 to May
2011 were evaluated for the present study. They had lo-
cally advanced resectable disease (cT3 or cT4) with the
inferior tumor margin located no further than 8 cm
from the anal verge. The study participants included 14
men and 6 women, with a median age of 61 years (range,
39–77 years). This study was approved by the institu-
tional review board of the Catholic University of Korea
(KC10EIMS0025).
During treatment, patients were immobilized in the
prone position using a foam cushion which covered the
whole body. A contrast-enhanced CT was scanned for
the treatment plan. Patients were instructed to have an
empty bladder before the planning CT scan. The CT im-
aging ranged from the L1 vertebral body to 5 cm below
the perineum, and axial images were obtained at 3-mm
thickness and imported to the Pinnacle3 treatment plan-
ning system (Philips Radiation Oncology Systems, Fitch-
burg, WI).
Treatment planning
Target volumes were defined according to the recom-
mendation of the ICRU report 62 [11]. The clinical
target volume included the gross tumor volume and the
presacral, mesorectal, common and internal iliac lymph
nodes. The planning target volume (PTV) was
Table 2 Comparison of irradiation doses to the organs at risk between Tomotherapy and 3-dimensional conformal
radiation therapy
Organs at risk Tomotherapy, mean (Gy) 3D-CRT, mean (Gy) p value
Small bowel 8.25 ± 2.24 12.34 ± 3.69 < 0.001
Bladder 14.95 ± 2.93 20.15 ± 2.13 < 0.001
Right femur head 11.05 ± 1.74 17.72 ± 1.46 < 0.001
Left femur head 10.80 ± 1.75 17.74 ± 1.38 < 0.001
3D-CRT 3-dimensional conformal radiation therapy.
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around the clinical target volume. The OARs such as
bladder, small bowel, and femur heads were contoured.
The small bowel was outlined 3 cm above and below the
PTV, and the bladder and femur heads were fully
outlined.
For the IMRT plan with Tomotherapy, the raw dosi-
metric data set of each patient was transferred from the
Pinnacle3 treatment planning system to the
Tomotherapy work-station (Figure 1A). For the 3D-CRT
plan, a three-field technique (one anterior portal and
two bilateral portals with wedge) was used (Figure 1B).
Twenty-five Gy in five fractions delivered with 6 to 15
MV photon was prescribed for the PTV. Dose con-
straints for the PTV were as follows; (1) ≥ 98% of the
PTV receives ≥ 95% of the prescribed dose, (2) ≤ 10% of
the PTV receives ≥ 105% of the prescribed dose, (3) ≤ 5%
of the PTV receives ≥ 110% of the prescribed dose. (4)
None of the PTV receives ≥ 115% of the prescribed dose.
No specific dose constraints for the OARs were used.
Dosimetric evaluation
Dosimetric parameters to analyze target coverage and
dose distribution in the PTV are as follows; (1) mean
dose, (2) VnGy, percentage of the volume receiving radi-
ation ≥ n Gy, (3) Dmin, minimum dose irradiated to the
PTV, (4) Dmax, maximum dose irradiated to the PTV, (5)
Radiation conformality index (RCI), PTV / V95% (volume
enclosed by the 95% of isodose line), and (6) RadicalTable 3 Comparison of dose parameters for the small
bowel between Tomotherapy and 3-dimensional
conformal radiation therapy
Values Tomotherapy, mean (Gy) 3D-CRT, mean (Gy) p value
V25Gy (%) 0.10 ± 0.24 10.92 ± 12.63 < 0.001
V22.5Gy (%) 0.93 ± 1.10 19.88 ± 15.73 < 0.001
V20Gy (%) 3.79 ± 6.23 25.32 ± 16.44 < 0.001
V17.5Gy (%) 8.19 ± 12.06 33.10 ± 18.71 < 0.001
V15Gy (%) 13.79 ± 20.65 30.28 ± 19.16 < 0.001
V10Gy (%) 30.28 ± 13.97 48.55 ± 19.03 0.001
V5Gy (%) 73.74 ± 22.82 77.30 ± 15.64 0.568
VnGy percentage of the volume receiving radiation ≥ n Gy.
3D-CRT 3-dimensional conformal radiation therapy.dose homogeneity index (rDHI): Dmin / Dmax in the
PTV. The avoidance of irradiation to the bladder, small
bowel, and femur heads was evaluated using the values
such as mean dose and VnGy.
The dosimetric parameters of Tomotherapy and 3D-
CRT were compared using the t-test and the difference
was considered statistically significant at the p < 0.05
level.
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Results
Dose distribution of the planning target volume (PTV)
The median of the PTV outlined in the 20 patients was
1076 cc (range, 796 to 1435 cc). The Tomotherapy and
3D-CRT plan met the prescription requirements for the
PTV in all cases. Dose parameters for the PTV in the
Tomtherapy and 3D-CRT plan were listed and com-
pared in Table 1. The mean PTV dose for Tomotherapy
is significantly higher than that for the 3D-CRT (25.58 ±
0.35 vs. 25.19 ± 0.74 Gy, p = 0.043). However, there were
no significant differences in the V23.25Gy, V26.25Gy, and
V27.5Gy values between the Tomotherapy and 3D-CRT.
Average Dmax values for the Tomotherapy and 3D-CRT
were not significantly different. However, the average
Dmin value for the Tomotherpay was significantly lower
than that for the 3D-CRT (17.97 ± 1.93 vs. 22.05 ±
2.76 Gy, p < 0.001), and average rDHI value for the
Tomotherapy is significantly lower than that for the 3D-
CRT plan (0.70 ± 0.01 vs. 0.83 ± 0.04, p < 0.001). The
average RCI values for the Tomotherapy and 3D-CRT
were 1.01 and 1.00, respectively, and there is no signifi-
cant difference in the average RCI value between the
two modalities.
Avoidance of organs at risk (OARs)
Table 2 shows the mean irradiation doses of the OARs
including the bladder, small bowel, and femur heads.
The mean doses for the bladder, small bowel, and femur
heads with the Tomotherapy were significantly lower
than those reported for the 3D-CRT.
Figure 2 Tomotherapy significantly reduced the V25Gy, V22.5Gy, V20Gy, V17.5Gy , V15Gy, and V10Gy value of the small bowel as compared to
3D-CRT. However, the V5Gy value which had been associated with the low irradiation range of the normal tissue was not significantly different
between the two modalities.
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small bowel, which is the most critical organ in the rec-
tal cancer patients who received the preoperative pelvic
irradiation. Table 3 summarizes the V25Gy, V22.5Gy, V20Gy,
V17.5Gy , V15Gy, V10Gy, and V5Gy values of the small bowel
with Tomotherapy and 3D-CRT. Tomotherapy produced
significantly lower V25Gy, V22.5Gy, V20Gy, V17.5Gy , V15Gy,
and V10Gy values for the small bowel as compared to the
3D-CRT. However, the V5Gy value, which reflected the
low irradiation range of the normal tissue, was not sig-
nificantly different between Tomotherapy and 3D-CRT
(Figure 2).
Discussion
IMRT modulates the beam intensity in several portals and
has been demonstrated to achieve an effective coverage of
the target tissue while avoiding damage to the normal tis-
sue during treatment. Recently, IMRT has established an
important role for the treatment of several malignancies
through the promise of excellent local control of disease
and reducing the potential complications inherent to exter-
nal irradiation. Luxton G et al. reported that the accurate
delivery of IMRT for prostate cancer could limit the dose
to normal tissues and allow for a reduction in the rate of
complication while maintaining the probability of tumor
control [12]. A report by Bazan JG et al. indicated that
IMRT was associated with less gastrointestinal, dermato-
logic, and hematologic toxicities, reduced need for treat-
ment breaks, and excellent tumor control, compared with
3D-CRT in patients with anal cancer [13]. The National
Comprehensive Consensus Network guidelines also rec-
ommend IMRT for the treatment of anal cancer patients in
addition to 3D-CRT [14].
In rectal cancer patients, the preoperative short-course
pelvic irradiation has demonstrated a definitive efficacy in
reducing the local failure rate, compared with the ratesreported for surgery alone [4,5]. However, it has given rise
to the incidence of late small bowel morbidities such as in-
testinal obstruction and chronic diarrhea that could alter
the therapeutic ratio [7,8]. Prognostic factors that increase
the risk of late small bowel complications include extended
fields out of the pelvis, irradiation dose, inappropriate ir-
radiation technique, and increased small bowel irradiated
volumes [15]. The irradiation dose and volume of the small
bowel in rectal cancer patients are of major concern to cli-
nicians [16]. Thus, we evaluated the dosimetric parameters
of IMRT with Tomotherapy in rectal cancer patients. We
hypothesized that Tomotherpay could reduce the overall
dose to the normal tissue while maintaining the dose to
the target, as compared to treatment with 3D-CRT.
In our study, the mean PTV dose for Tomotherapy is
significantly higher than that for the 3D-CRT (25.58 ± 0.35
vs. 25.19 ± 0.74 Gy, p = 0.043) while Tomotherapy
maintaining ≥ 98% of the PTV receives ≥ 95% of the pre-
scribed dose and ≤ 10% of the PTV receives ≥ 105% of the
prescribed dose. However, the rDHI for Tomotherapy is
significantly lower than that for the 3D-CRT (0.70 ± 0.01
vs. 0.83 ± 0.04, p < 0.001) since the average Dmin value for
the Tomotherpay was significantly lower than that for the
3D-CRT (17.97 ± 1.93 vs. 22.05 ± 2.76 Gy, p < 0.001). Local
tumor control is related to the mean dose rather than to
the minimum dose in the target [17]. Moreover, a modest
number of cold spots are not related to the reduced tumor
control, and it is important to know the location and vol-
ume of the cold spots [18]. When we have checked our
Tomotherapy plans to identify the location of cold spots,
they were very small and were predominantly located in
the small bowel region adjacent to the PTV, which had a
low probability of tumor involvement.
In our analysis, Tomotherapy significantly reduced the
mean dose irradiated to the OARs such as bladder, small
bowel, and femur heads as compared to 3D-CRT.
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intermediate irradiation range (V25Gy, V22.5Gy, V20Gy,
V17.5Gy, V15Gy, and V10Gy) to the small bowel compared to
3D-CRT. However, the V5Gy values which meant by low ir-
radiation range of the radiation dose were similar between
the Tomotherapy and 3D-CRT.
The result of the IMRT plans was associated with a
trade-off between the coverage of the target and avoid-
ance of the OSRs. We could attain optimal Tomotherapy
plans, which significantly reduced the mean irradiation
dose to the OARs at the expense of acceptable dose in-
homogeneity of the PTV, because the goal of our IMRT
plans was sparing of the OARs rather than full coverage
of the target. Even though our study had inherent limita-
tions including the retrospective nature and small pa-
tient number, our results support further investigation of
IMRT for the treatment of rectal cancer patients [19-22].
In conclusion, our study shows that the use of
Tomtherapy could produce favorable coverage for the
target and decrease the mean dose for the OARs as
compared to 3D-CRT for treatment of patients with rec-
tal cancer. For a definitive conclusion, the Tomotherapy
technique should be tested and compared with conven-
tional radiation in a prospective series.
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